Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 1/17/14  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Franklin Pass

Wrong Dr. Franklin Pass?

Chief Executive Officer

Martell Biosystems , Inc.
 
Background

Employment History

Board Memberships and Affiliations

Education

  • MD
  • University of Minnesota
  • University of Minnesota Medical School
26 Total References
Web References
SEC EDGAR Submission 0001193125-05-061028
www.sec.gov, 25 Mar 2005 [cached]
Continuing as directors for the Company but not subject to re-election were directors Frank Massino, George Fellows, Kevin McCarthy, Anthony Williams and Dr. Franklin Pass.
...
Franklin Pass
Director
...
Dr. Franklin Pass was appointed a director in February 2002.Since March 2001 he has been Vice Chairman of Antares Pharma, Inc., which develops and markets pharmaceutical delivery systems, and is Managing Director at Cherry Tree Securities, a Minnesota-based investment banking group which provided consulting services to the Company from January 2002 to June 2002.Since 2003 Dr. Pass has also served as a Director of Peptx, Inc., a privately held venture stage drug development company.Previously, Dr. Pass was Chairman and CEO of Antares Pharma, Inc., BioSeeds International, Ltd., and Molecular Genetics, Inc. (MGI Pharma, Inc.), which he co-founded.He served as CEO of Medi-ject Corp. from 1993 to 2001.He has served as Director of the American Academy of Dermatology, Director of Dermatology at the Albert Einstein College of Medicine, and Clinical Professor at the University of Minnesota, Department of Dermatology.He received his medical degree from the University of Minnesota, School of Medicine.
...
The Board of Directors has determined that Dr. Franklin Pass, a member of the Audit Committee, qualifies as an "audit committee financial expert," and is "independent," as defined in applicable SEC rules.
Of the current Directors, two are ...
www.sec.gov, 3 Nov 2003 [cached]
Of the current Directors, two are Managing or Executive Directors, and three were appointed by the Board of Directors since the last Annual Meeting, leaving only two Directors subject to this rule, namely Franklin Pass and Uwe Thieme.
...
Franklin Pass
Director
...
Dr. Franklin Pass was appointed a Director in February 2002.Since March 2001, he has been Vice Chairman of Antares Pharma, Inc. (formerly known as Mediject Corporation), which develops and markets pharmaceutical delivery systems, and is a Managing Director of Cherry Tree Development LLC, a Minnesota-based investment banking group.From 1993 to 2000, Dr. Pass was Chairman and CEO of Mediject Corporation.He has served as Director of the American Academy of Dermatology, Director of Dermatology at the Albert Einstein College of Medicine, and Clinical Professor at the University of Minnesota, Department of Dermatology.He received his medical degree from the University of Minnesota, School of Medicine.
...
Tobler and Georgiev were replaced on the Committee by Dr. Pass and Mr. Nichols, a former Director.
...
Upon Mr. Fellows' election to the Board, Dr. Pass was replaced on the Committee by Mr. Fellows.
...
Williams and McCarthy, Mr. Tobler and Dr. Pass were replaced on the Committee by Messrs.
...
The special task force was in existence from February through May 2002 and consisted of Dr. Pass, Mr. Tobler and Wade Nichols, a former Director.
...
Dr. Pass and Messrs.
...
The aggregate amounts received by the various Directors or their affiliated companies for consulting services during 2002, including consulting services provided as a member of the special task force, were: Mr. Pass, $30,000; Mr. Tobler, $139,000; Mr. Nichols, $105,000.
...
Total option grants were: Mr. Tobler, 225,000 shares, Mr. Nichols (a former Director), 150,000 shares, Mr. Georgiev (a former Director), 225,000 shares, and Dr. Pass, 150,000 shares.
...
Franklin Pass
...
Includes the following number of shares issuable upon exercise of options that are currently exercisable or will become exercisable within 60 days of September 15, 2003: Mr. Massino: 2,575,000; Dr. Thieme: 280,000; Mr. Tobler: 845,000; Mr. Slade: 172,500; Dr. Pass: 150,000; Mr. Nichols: 150,000.
...
From June 16, 2003 to September 16, 2003, the Company engaged Cherry Tree Development, LLC ("CTD"), an affiliate of Cherry Tree Securities, of which Dr. Pass is a Managing Director, as the Company's financial advisor in connection with the possible sale or licensing of the Company's patented Invicorp® erectile dysfunction product and Reliaject® autoinjector.During that period, CTD was paid a retainer of $12,000 per month plus expenses and, if a covered transaction occurs within a specified period, would be entitled to a fee equal to 8% of each of (i) all consideration received by the Company at the time of sale or licensing, (ii) milestone payments and (iii) developmental payments, less monthly fees paid.In addition, CTD was paid the $30,000 in consulting fees due to Dr. Pass for his special task force services from April 2002 to June 2002 described under "Board Meetings, Committees and Compensation" above.
Investment Banking Team
www.cherrytree.com, 30 May 2006 [cached]
Frank Pass | Managing Director
...
Franklin Pass, MDFranklin Pass has operated as an entrepreneur in the agricultural biotechnology and pharmaceutical business sectors for 25 years.He has been the co-founder and/or CEO of five life sciences business ventures, two of which became public corporations under his leadership.Dr. Pass was formerly a research dermatologist and at one time headed the dermatology program at Albert Einstein College of Medicine.He has been active in his profession, serving as Secretary-Treasurer of the American Academy of Dermatology for six years and as cofounder of the Industrial Biotechnology Association, now known as BIO.He has participated as director of two regional arts organizations.He is the graduate of the University of Minnesota and the University of Minnesota Medical School.Dr. Pass can be found many summer evenings on his favorite nearby trout stream.
Franklin Pass, M.D., is ...
www.martellbiosystems.com, 5 Aug 2011 [cached]
Franklin Pass, M.D., is Chairman and CEO. During a forty-year career in academic medicine and early stage biotechnology businesses, Frank pioneered the fields of papilloma virus biology and genetic modification of agricultural crops. He was co-founder of three public biotechnology companies, is Chairman of Nidus Laboratories, Inc., and a Director of TerraMax, Inc. and PepTx, Inc. He is Senior Medical Advisor to Cherry Tree companies, a boutique investment banking firm.
Investment Banking Team
www.cherrytree.com, 22 Sept 2011 [cached]
Frank Pass Senior Advisor
Other People with the name "Pass":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304